Could this be the best ASX healthcare stock in 2020?

The Polynovo Limited (ASX: PNV) share price is up over 300% in just 12 months. But this could still be just the beginning of its growth story.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares in ASX healthcare company Polynovo Limited (ASX: PNV) have been on a tear recently. Since the beginning of this year, Polynovo's share price has surged over 55% to $3.07 as at the time of writing.

But the charge really began a lot earlier than 2020: longer-term shareholders who have held Polynovo for at least 12 months are now sitting on gains of well over 300%.

Why is Polynovo's share price skyrocketing?

Polynovo is a junior healthcare company which specialises in the development of biodegradable medical devices to aid in tissue repair. Its flagship medical technology is called NovoSorb, which was originally developed by the CSIRO. It is a medical grade polymer designed for use in surgery, tissue repair, and other medical procedures and will safely biodegrade and be excreted by the body.

Novosorb BTM is the first fully commercialised Novosorb product developed by Polynovo. It is a synthetic polymer matrix that clinicians can use to treat serious burn victims. The polymer can be applied to burns and trauma sites on the body and will encourage the construction of new skin tissue, before being eventually absorbed and excreted, leaving only biological material behind.

The reason behind Polynovo's share price growth is the underlying momentum of the company. The last couple of months have been very strong for Polynovo. In early January it announced that December was the first month in which it had generated more than $2 million in sales. And while CEO Paul Brennan warned that sales could continue to be "lumpy", it was still a significant milestone for Polynovo, especially considering that the first time the company had generated $1 million in sales in a single month was as recently as April 2019.

Sales growth could continue to accelerate throughout 2020 as Novosorb breaks into new overseas markets.

Soon after, Polynovo also announced that Novosorb BTM had been used in surgical operations in the UK, Germany and Switzerland, and that orders had also been placed for the product in Austria.

Plus, Polynovo has already entered the US market. In a recent interview with Alan Kohler, Paul Brennan stated that Polynovo was supplying various hospitals in the US, and last year the company announced it had been granted access to the US Department of Defence.

In the same interview with Alan Kohler, Paul Brennan laid out his aggressive growth strategy, which should please long-term investors. Although Brennan confirmed that Polynovo had delivered a number of profitable months recently, he stated he was more inclined to invest that money back into the business rather than necessarily announce an overall profit for the half year.

While this strategy might turn off short-term investors seeking an earnings surprise from Polynovo's half-year results announcement (which is due at the end of the month), it should reassure shareholders that management has the longer-term goals of the company in mind when making business decisions.

Foolish Takeaway

Along with other junior healthcare companies like Paradigm Biopharmaceuticals Limited (ASX: PAR), Medical Developments International Limited (ASX: MVP) and Opthea Limited (ASX: OPT), Polynovo is an exciting investment prospect. It has already commercialised its biotechnology, is expanding globally and is pursuing an aggressive growth strategy.

This isn't to say it isn't risky. It is still a young company with a short track record, and there is always the chance its technology will be superseded by something else. It should also be noted that a few uses of its product in Germany and Switzerland doesn't necessarily mean it will be adopted by hospitals all across Europe.

But for those investors wishing to take some degree of risk and back a growing healthcare company, Polynovo makes for an attractive investment. Novosorb is an exciting technology with potentially wide medical applications, and its growth story is difficult to ignore.

Rhys Brock owns shares of Medical Developments International Limited. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Medical Developments International Limited. The Motley Fool Australia has recommended Medical Developments International Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

A happy young couple lie on a wooden deck using a skateboard for a pillow.
Share Gainers

These were the best-performing ASX 200 shares in March

These shares made their shareholders smile in March thanks to some very big gains.

Read more »

Businessman using a digital tablet with a graphical chart, symbolising the stock market.
Opinions

2 ASX shares I have been buying in 2024!

I’m a believer in the long-term outlook of these stocks.

Read more »

Stock market chart in green with a rising arrow symbolising a rising share price.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a massive day for the ASX 200, with a new all-time high recorded.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Technology Shares

This ASX tech stock rocketed 60% in March! Can it keep on delivering?

After soaring in March, the ASX tech stock is now up 169% since this time last year.

Read more »

Broker Notes

Brokers name 3 ASX shares to buy now

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A young man clasps his hand to his head with his eyes closed and a pained expression on his face as he clasps a laptop computer in front of him, seemingly learning of bad news or a poor investment.
Share Fallers

Why Burgundy Diamond Mines, Clarity Pharmaceuticals, EML, and Zip are sinking today

These ASX shares are ending the week in the red. But why?

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop.
Share Gainers

Why Mesoblast, Newmont, Pilbara Minerals, and Platinum shares are jumping

These ASX shares are ending the week strongly. But why?

Read more »

a young boy dressed up in a business suit and tie has a cute grin and holds two fingers up.
Opinions

2 of my top ASX 200 shares to consider buying before April

I would happily exchange dollars for these two shares right now.

Read more »